Table 2.
Base Case Results Assuming 20% Wild-Type Virus at Confirmed First-line Antiretroviral Therapy Failure
| Base Case Result | Time on Second-line ARTa (mo) | Undiscounted Life Expectancy (mo) | Discounted Life Expectancy (mo) | Discounted Cost ($) | Cost-effectiveness ($/YLS) |
|---|---|---|---|---|---|
| Cohort-based outcomes | |||||
| No genotype WT virus | 93.9 | 115.4 | 93.9 | 15 350 | |
| No genotype resistant virus | 109.1 | 136.5 | 109.1 | 16 610 | |
| Genotype WT virus | 80.1 | 149.6 | 116.5 | 16 220 | |
| Genotype resistant virus | 106.2 | 132.5 | 106.2 | 16 620 | |
| Strategy-based outcomes, weighted average, by prevalence of resistance | |||||
| No genotype | 106.1 | 132.3 | 106.1 | 16 360 | … |
| Genotype | 101.0 | 135.9 | 108.3 | 16 540 | 900 |
Abbreviation: ART, antiretroviral therapy; WT, wild-type; YLS, year of life saved.
a Less time on protease inhibitor–based second-line ART confers decreased costs because second-line ART is more expensive than nonnucleoside reverse transcriptase inhibitor–based first-line ART and is the last available regimen.